Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Next Previous
Trial Profile

Phase I Study of Combination of Nab-paclitaxel, Gemcitabine, and Bevacizumab in Advanced Malignancies

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Mar 2018

At a glance

  • Drugs Bevacizumab (Primary) ; Gemcitabine (Primary) ; Paclitaxel (Primary)
  • Indications Cancer; Oesophageal cancer; Ovarian cancer; Pancreatic cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 01 Mar 2018 Planned End Date changed from 1 Apr 2019 to 1 Apr 2021.
    • 01 Mar 2018 Planned primary completion date changed from 1 Apr 2019 to 1 Apr 2020.
    • 01 Mar 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top